文献速递膀胱癌与上尿路尿路上皮癌

胚系DNA修复基因突变与膀胱癌风险及不良预后相关

Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis.
PubMed 文献 · BJU Int · 2018-06-04

该研究对98例膀胱癌患者进行54个DNA修复基因的靶向测序,并与公共数据库对照比较突变频率。致病/可能致病性胚系DNA修复基因突变频率为10.2%,肌层浸润性膀胱癌中为15.8%,早发性(<45岁)患者中为28.57%;突变携带者不良临床结局频率显著更高(50.0% vs 13.64%,P=0.013)。

要点

  • 膀胱癌患者胚系DNA修复基因致病突变频率为10.2%。
  • 肌层浸润性膀胱癌突变频率15.8%,约为非肌层浸润性(6.67%)的2.4倍。
  • 突变携带者不良结局(复发或转移进展)频率显著高于非携带者。

核心结论

  • 胚系DNA修复基因致病及可能致病突变与膀胱癌不良预后相关。

研究设计与样本

  • 对98例膀胱癌患者胚系DNA使用定制靶向测序面板分析54个DNA修复基因。
  • 群体对照数据来自Exome Aggregation Consortium和Genome Aggregation Database公共数据库。
  • 突变致病性依据美国医学遗传学与基因组学学会标准、一般人群突变频率和ClinVar数据库注释。
  • 采用病例-对照和病例-病例设计比较突变频率,分析疾病风险、侵袭性和结局。

主要发现

  • 致病/可能致病性胚系DNA修复基因突变在膀胱癌患者中频率为10.2%。
  • 肌层浸润性膀胱癌患者突变频率为15.8%,约为非肌层浸润性膀胱癌(6.67%)的2.4倍。
  • 早发性(<45岁)患者突变频率为28.57%,约为45岁后诊断者(8.79%)的3倍。
  • 突变携带者不良临床结局(疾病复发或进展为转移性膀胱癌)频率显著高于非携带者(50.0% vs 13.64%;P=0.013)。

临床怎么用

  • 对膀胱癌患者,尤其肌层浸润性、早发性或有不良结局者,可考虑胚系DNA修复基因检测以评估预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To perform a systematic evaluation of whether germline DNA repair gene mutations in bladder cancer (BCa) are associated with increased risk of BCa and aggressive disease. MATERIALS AND METHODS: Germline DNA from 98 patients with BCa was analysed for 54 DNA repair genes using a customized targeted sequencing panel. Population control data were obtained from the public databases the Exome Aggregation Consortium database and the Genome Aggregation Database. Mutation pathogenicity was annotated based on American College of Medical Genetics criteria, mutation frequencies in the general population and the ClinVar database. Mutation frequencies were compared based on case-control and case-case designs for disease risks, disease aggressiveness and outcomes. RESULTS: The frequency of pathogenic/likely pathogenic germline DNA repair gene mutations was 10.2% among patients with BCa. Within the subset of patients with carcinoma invading the bladder muscle, the frequency was 15.8%, ~2.4-fold higher than in patients with non-muscle invasive BCa (6.67%). The mutation frequency among patients with early-onset disease (at age <45 years) was ~3-fold higher than among those diagnosed after age 45 years (28.57% vs 8.79%). Mutation carriers had a significantly higher frequency of unfavourable clinical outcomes (disease recurrence or progression to metastatic BCa) than non-carriers (50.0% vs 13.64%; P = 0.013). CONCLUSION: Pathogenic and likely pathogenic mutations in DNA repair genes were associated with unfavourable prognosis of BCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Na R, Wu Y, Jiang G, et al. Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis. BJU Int. 2018. PMID: 29727914. doi:10.1111/bju.14370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。